Major cardiovascular event risk of advanced therapies in inflammatory bowel diseases: systematic review and meta-analysis.
Amirah H Alnahdi, Chelsea Salmon, Fanxing Du et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the risk of major adverse cardiovascular events (MACE) associated with advanced therapies in patients with inflammatory bowel disease (IBD). Analyzing 43 studies, including 36 randomized controlled trials, the findings indicated a nonsignificant trend toward reduced MACE risk with advanced therapies (OR 0.60; 95% CI 0.24-1.51), highlighting the need for further research to clarify these associations.
Key findings
- Advanced therapies showed a nonsignificant trend toward reduced MACE risk (OR 0.60; 95% CI 0.24-1.51).
- IL-12/IL-23 inhibitors suggested lower MACE risk (OR 0.35; 95% CI 0.05-2.21).
- Anti-TNF agents indicated a potential increase in MACE risk (OR 3.04; 95% CI 0.31-29.47).
- Observational studies suggested lower MACE risk with Anti-TNF therapies (OR 0.29; 95% CI 0.21-0.40).
Why it matters
Understanding the cardiovascular risks associated with advanced therapies in IBD is crucial for clinicians managing these patients, as it informs treatment decisions and patient counseling regarding potential cardiovascular outcomes.